NEW YORK (GenomeWeb News) – Compugen said today that it had discovered and experimentally verified a variant of the Troponin I biomarker, and that it has granted an option to Biosite to develop the biomarker for immunoassay diagnostic products.
Compugen said that the variant, CGEN-144, has been verified to be differentially expressed as serum protein in myocardial infarction patients compared to healthy individuals. The Israel-based firm said that the Troponin variant, for which it was granted a US patent, was predicted by its immunoassay biomarker computational discovery platform.
Under the pact with Biosite, Compugen will provide Biosite with existing proprietary data related to the molecule. Biosite will develop and select antibodies that bind to the molecule to determine assay sensitivity and specificity in various disease states and as an addition to the currently commercialized Troponin I test.
The alliance also provides Biosite with an option to obtain worldwide, royalty-bearing rights to commercialize an immunoassay diagnostic product based on CGEN-144.
Biosite, which had 2006 revenue of $309 million, derives roughly 80 percent of its sales from cardiovascular tests. Last year, the firm was acquired by Inverness Medical Innovations for approximately $1.72 billion, after Beckman Coulter pulled out of a bidding war.